Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins

Eur J Cancer. 2017 Aug:81:203-205. doi: 10.1016/j.ejca.2017.05.018. Epub 2017 Jun 20.

Authors

Iris Spänkuch¹, Maximilian Gassenmaier¹, Ioanna Tampouri¹, Seema Noor¹, Andrea Forschner¹, Claus Garbe², Teresa Amaral³

Affiliations

¹ Center for Dermatooncology, Department of Dermatology, Liebermeisterstr. 25, University Hospital Tuebingen, 72076 Tuebingen, Germany.
² Center for Dermatooncology, Department of Dermatology, Liebermeisterstr. 25, University Hospital Tuebingen, 72076 Tuebingen, Germany. Electronic address: [email protected].
³ Center for Dermatooncology, Department of Dermatology, Liebermeisterstr. 25, University Hospital Tuebingen, 72076 Tuebingen, Germany; Portuguese Air Force Health Direction, Paço Do Lumiar, 1649-020 Lisbon, Portugal.

PMID: 28641200
DOI: 10.1016/j.ejca.2017.05.018

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adrenal Cortex Hormones / administration & dosage*
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chemical and Drug Induced Liver Injury / drug therapy*
Female
Hepatitis / drug therapy*
Hepatitis / immunology
Humans
Immunoglobulins / administration & dosage*
Immunotherapy / adverse effects
Ipilimumab / administration & dosage
Ipilimumab / adverse effects
Melanoma / drug therapy
Melanoma / pathology
Middle Aged
Nivolumab
Severity of Illness Index
Skin Neoplasms / drug therapy
Skin Neoplasms / pathology
Thymocytes / immunology*

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins
Ipilimumab
Nivolumab